Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Inflammation
Published in: Inflammation 3/2012

01-06-2012

Barrier Protective Activities of Phloroglucinol on Lipopolysaccharide (LPS)-Induced Barrier Disruption in Human Endothelial Cells

Author: Jong-Sup Bae

Published in: Inflammation | Issue 3/2012

Login to get access

Abstract

Phloroglucinol plays an important role in oxidative stress, inflammatory responses, and matrix metalloproteinase (MMP) regulation. However, the barrier protective functions of phloroglucinol are not well studied. The objective of this study was to fill this gap. We did this by investigating the barrier protective activities of phloroglucinol on lipopolysaccharide (LPS)-induced barrier disruption in human endothelial cells measured by cellular permeability, monocytes adhesion, and migration toward human endothelial cells. The results showed that phloroglucinol inhibited LPS-induced barrier hyperpermeability, monocyte adhesion, and migration. These inhibitory effects were significantly correlated with the inhibitory functions of phloroglucinol on LPS-induced cell adhesion molecules. Furthermore, LPS-induced nuclear factor-κB (NF-κB) and tumor necrosis factor-κB (TNF-κB) release from human umbilical vein endothelial cells (HUVECs) was inhibited by phloroglucinol. Given these results, phloroglucinol could be a candidate as a therapeutic agent for various systemic inflammatory diseases.
Literature
1.
He, P. 2010. Leucocyte/endothelium interactions and microvessel permeability: Coupled or uncoupled? Cardiovascular Research 87: 281–290.PubMedCrossRef
2.
Weis, S.M. 2008. Vascular permeability in cardiovascular disease and cancer. Current Opinion in Hematology 15: 243–249.PubMedCrossRef
3.
Nooteboom, A., T. Hendriks, I. Otteholler, and C.J. van der Linden. 2000. Permeability characteristics of human endothelial monolayers seeded on different extracellular matrix proteins. Mediators of Inflammation 9: 235–241.PubMedCrossRef
4.
Dudek, S.M., and J.G. Garcia. 2001. Cytoskeletal regulation of pulmonary vascular permeability. Journal of Applied Physiology 91: 1487–1500.PubMed
5.
Raetz, C.R., and C. Whitfield. 2002. Lipopolysaccharide endotoxins. Annual Review of Biochemistry 71: 635–700.PubMedCrossRef
6.
Gao, X., N. Xu, M. Sekosan, et al. 2001. Differential role of CD18 integrins in mediating lung neutrophil sequestration and increased microvascular permeability induced by Escherichia coli in mice. Journal of Immunology 167: 2895–2901.
7.
Hirano, S., R.S. Rees, S.L. Yancy, et al. 2004. Endothelial barrier dysfunction caused by LPS correlates with phosphorylation of HSP27 in vivo. Cell Biology and Toxicology 20: 1–14.PubMedCrossRef
8.
Berman, R.S., J.D. Frew, and W. Martin. 1993. Endotoxin-induced arterial endothelial barrier dysfunction assessed by an in vitro model. British Journal of Pharmacology 110: 1282–1284.PubMed
9.
Goldblum, S.E., X. Ding, T.W. Brann, and J. Campbell-Washington. 1993. Bacterial lipopolysaccharide induces actin reorganization, intercellular gap formation, and endothelial barrier dysfunction in pulmonary vascular endothelial cells: Concurrent F-actin depolymerization and new actin synthesis. Journal of Cellular Physiology 157: 13–23.PubMedCrossRef
10.
Javaid, K., A. Rahman, K.N. Anwar, R.S. Frey, R.D. Minshall, and A.B. Malik. 2003. Tumor necrosis factor-alpha induces early-onset endothelial adhesivity by protein kinase Czeta-dependent activation of intercellular adhesion molecule-1. Circulation Research 92: 1089–1097.PubMedCrossRef
11.
Lockyer, J.M., J.S. Colladay, W.L. Alperin-Lea, T. Hammond, and A.J. Buda. 1998. Inhibition of nuclear factor-kappaB-mediated adhesion molecule expression in human endothelial cells. Circulation Research 82: 314–320.PubMed
12.
Yamagami, H., S. Yamagami, T. Inoki, S. Amano, and K. Miyata. 2003. The effects of proinflammatory cytokines on cytokine-chemokine gene expression profiles in the human corneal endothelium. Investigative Ophthalmology & Visual Science 44: 514–520.CrossRef
13.
Zeuke, S., A.J. Ulmer, S. Kusumoto, H.A. Katus, and H. Heine. 2002. TLR4-mediated inflammatory activation of human coronary artery endothelial cells by LPS. Cardiovascular Research 56: 126–134.PubMedCrossRef
14.
Ahn, G., I. Hwang, E. Park, et al. 2008. Immunomodulatory effects of an enzymatic extract from Ecklonia cava on murine splenocytes. Marine Biotechnology 10: 278–289.PubMedCrossRef
15.
Ahn, M.J., K.D. Yoon, S.Y. Min, et al. 2004. Inhibition of HIV-1 reverse transcriptase and protease by phlorotannins from the brown alga Ecklonia cava. Biological & Pharmaceutical Bulletin 27: 544–547.CrossRef
16.
Kim, M.M., Q.V. Ta, E. Mendis, et al. 2006. Phlorotannins in Ecklonia cava extract inhibit matrix metalloproteinase activity. Life Science 79: 1436–1443.CrossRef
17.
Kim, T.H., and J.S. Bae. 2010. Ecklonia cava extracts inhibit lipopolysaccharide induced inflammatory responses in human endothelial cells. Food and Chemical Toxicology 48: 1682–1687.PubMedCrossRef
18.
Kang, H.S., H.Y. Chung, J.H. Jung, B.W. Son, and J.S. Choi. 2003. A new phlorotannin from the brown alga Ecklonia stolonifera. Chemical & Pharmaceutical Bulletin (Tokyo) 51: 1012–1014.CrossRef
19.
Li, Y., Z.J. Qian, B. Ryu, S.H. Lee, M.M. Kim, and S.K. Kim. 2009. Chemical components and its antioxidant properties in vitro: An edible marine brown alga, Ecklonia cava. Bioorganic & Medicinal Chemistry 17: 1963–1973.CrossRef
20.
Kim, M.M., and S.K. Kim. 2010. Effect of phloroglucinol on oxidative stress and inflammation. Food and Chemical Toxicology 48: 2925–2933.PubMedCrossRef
21.
Glombitza, K.W., S. Hauperich, and M. Keusgen. 1997. Phlorotannins from the brown algae Cystophora torulosa and Sargassum spinuligerum. Natural Toxins 5: 58–63.PubMedCrossRef
22.
Kang, K.A., K.H. Lee, S. Chae, et al. 2006. Cytoprotective effect of phloroglucinol on oxidative stress induced cell damage via catalase activation. Journal of Cellular Biochemistry 97: 609–620.PubMedCrossRef
23.
Bae, J.S., and A.R. Rezaie. 2008. Protease activated receptor 1 (PAR-1) activation by thrombin is protective in human pulmonary artery endothelial cells if endothelial protein C receptor is occupied by its natural ligand. Thrombosis and Haemostasis 100: 101–109.PubMed
24.
Akeson, A.L., and C.W. Woods. 1993. A fluorometric assay for the quantitation of cell adherence to endothelial cells. Journal of Immunological Methods 163: 181–185.PubMedCrossRef
25.
Che, W., N. Lerner-Marmarosh, Q. Huang, et al. 2002. Insulin-like growth factor-1 enhances inflammatory responses in endothelial cells: Role of Gab1 and MEKK3 in TNF-alpha-induced c-Jun and NF-kappaB activation and adhesion molecule expression. Circulation Research 90: 1222–1230.PubMedCrossRef
26.
Marui, N., M.K. Offermann, R. Swerlick, et al. 1993. Vascular cell adhesion molecule-1 (VCAM-1) gene transcription and expression are regulated through an antioxidant-sensitive mechanism in human vascular endothelial cells. Journal of Clinical Investigation 92: 1866–1874.PubMedCrossRef
27.
Wung, B.S., C.W. Ni, and D.L. Wang. 2005. ICAM-1 induction by TNFalpha and IL-6 is mediated by distinct pathways via Rac in endothelial cells. Journal of Biomedical Science 12: 91–101.PubMedCrossRef
28.
Hansson, G.K., and P. Libby. 2006. The immune response in atherosclerosis: A double-edged sword. Nature Reviews Immunology 6: 508–519.PubMedCrossRef
29.
Osterud, B., and E. Bjorklid. 2003. Role of monocytes in atherogenesis. Physiological Reviews 83: 1069–1112.PubMed
30.
Yipp, B.G., G. Andonegui, C.J. Howlett, et al. 2002. Profound differences in leukocyte-endothelial cell responses to lipopolysaccharide versus lipoteichoic acid. Journal of Immunology 168: 4650–4658.
31.
Andonegui, G., S.M. Goyert, and P. Kubes. 2002. Lipopolysaccharide-induced leukocyte-endothelial cell interactions: A role for CD14 versus toll-like receptor 4 within microvessels. Journal of Immunology 169: 2111–2119.
32.
Moy, A.B., M. Winter, A. Kamath, et al. 2000. Histamine alters endothelial barrier function at cell–cell and cell-matrix sites. American Journal of Physiology. Lung Cellular and Molecular Physiology 278: L888–L898.PubMed
33.
Qiao, R.L., H.S. Wang, W. Yan, et al. 1995. Extracellular matrix hyaluronan is a determinant of the endothelial barrier. American Journal of Physiology 269: C103–C109.PubMed
34.
Granger, D.N., and P. Kubes. 1994. The microcirculation and inflammation: Modulation of leukocyte-endothelial cell adhesion. Journal of Leukocyte Biology 55: 662–675.PubMed
35.
Albelda, S.M., C.W. Smith, and P.A. Ward. 1994. Adhesion molecules and inflammatory injury. The FASEB Journal 8: 504–512.
36.
Muller, W.A. 2002. Leukocyte-endothelial cell interactions in the inflammatory response. Laboratory Investigation 82: 521–533.PubMedCrossRef
37.
Carlos, T.M., and J.M. Harlan. 1994. Leukocyte-endothelial adhesion molecules. Blood 84: 2068–2101.PubMed
Metadata
Title
Barrier Protective Activities of Phloroglucinol on Lipopolysaccharide (LPS)-Induced Barrier Disruption in Human Endothelial Cells
Author
Jong-Sup Bae
Publication date
01-06-2012
Publisher
Springer US
Published in
Inflammation / Issue 3/2012
Print ISSN: 0360-3997
Electronic ISSN: 1573-2576
DOI
https://doi.org/10.1007/s10753-011-9394-5

Other articles of this Issue 3/2012

Inflammation 3/2012 Go to the issue

OriginalPaper

Chlorophyll Revisited: Anti-inflammatory Activities of Chlorophyll a and Inhibition of Expression of TNF-α Gene by the Same

OriginalPaper

Investigation into the Anti-inflammatory and Antigranuloma Activity of Colchicum luteum Baker in Experimental Models

OriginalPaper

Therapeutic Potential of the Proteasome Inhibitor Bortezomib on Titanium Particle-Induced Inflammation in a Murine Model

OriginalPaper

A Distinct Regulatory Role of Th17 Cytokines IL-17A and IL-17F in Chemokine Secretion from Lung Microvascular Endothelial Cells

OriginalPaper

Antibacterial and Anti-inflammatory Activity of Traditional Chinese Herb Pairs, Angelica sinensis and Sophora flavescens

OriginalPaper

The IL-10 Promoter Polymorphism at Position −592 is Correlated with Susceptibility to Occult HBV Infection
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits